COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Loss Contingencies [Line Items] | ||||
| [custom:TerminationAgreementDescription] | The employment agreements as amended for the Company’s Executive Chairman and CEO each contain termination provisions whereby if they are terminated without cause or following a material change, as defined therein, they will receive salary through the date of termination plus an additional 24 months, bonus that would be earned during the full year when the termination became effective (or a lump sum of 50% of the full target bonus), all stock options shall vest and healthcare benefits will continue for 24 months. The Company’s General Counsel’s employment agreement, as amended, contains an 18-month severance payment in the instance of a termination without cause or following a material change, as defined therein | |||
| Stock issued during period shares new issues | 34,219 | 206,517 | ||
| Professional fees | $ 218,006 | $ 151,858 | $ 857,411 | $ 954,686 |
| Research and development expense | 204,216 | $ 147,453 | $ 459,053 | 221,407 |
| Chairman and CEO [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Description of nature and effects | The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiaries is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s General Counsel contains a similar transaction bonus equal to 0.5% of consideration received by the Company | |||
| Employment Agreements [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Accrued salaries | $ 588,805 | $ 588,805 | ||
| License Agreement [Member] | IGL Pharma Inc [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Other expenses | 60,000 | |||
| Stock issued during period shares new issues | 12,500 | |||
| Royalty percentage | 4.50% | |||
| Sublicense percentage | 5.00% | |||
| Payment for license fees | 60,000 | |||
| Professional fees | $ 8,500 | |||
| License Agreement [Member] | IGL Pharma Inc [Member] | Upon Commercialization [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Other expenses | 2,000,000 | |||
| License Agreement [Member] | IGL Pharma Inc [Member] | Maximum [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Other expenses | 410,000 | |||
| Consulting Agreement [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Research and development expense | 95,988 | $ 147,453 | ||
| Consulting Agreement [Member] | IGL Pharma Inc [Member] | ||||
| Loss Contingencies [Line Items] | ||||
| Other expenses | 9,355 | |||
| Rent payments | $ 8,500 | |||